What is Union Agener?
Union Agener Animal Health operates within the biotechnology sector, specifically targeting improvements in animal well-being and productivity. The company is recognized for its proprietary product, Posilac®, a recombinant bovine somatotropin designed to optimize milk yield in dairy cattle. By providing innovative solutions to dairy farmers and agricultural businesses, Union Agener aims to drive efficiency and sustainability within the livestock industry. Their commitment to research and development positions them as a key player in the evolving landscape of animal health.
How much funding has Union Agener raised?
Union Agener has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Union Agener
PPP
Public-Private Partnership
What's next for Union Agener?
The substantial enterprise-level funding and recent strategic investment signal a strong vote of confidence in Union Agener's business model and future prospects. This capital infusion is expected to fuel further innovation, potentially expanding the reach of Posilac® and other animal health products. Strategic partnerships and market penetration initiatives are likely to be prioritized, enabling Union Agener to solidify its position and capitalize on emerging opportunities within the global agricultural technology market. The company appears poised for significant scaling and continued development in the animal health domain.
See full Union Agener company page
